AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9250122 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10 mg elemental Zn daily for 6 months)
Number of subjects: 579
Study 8099118 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary treatment based upon weight reduction and recommendations about a low alcohol intake
Number of subjects: 64
Study 8099118 — intervention group
Group type: COMPARATOR
Intervention: Drug treatment using a stepped-care approach with atenolol as the first-choice drug
Number of subjects: 64
Study 3828192 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5 mg i.v. prochlorperazine
Number of subjects: 8
Study 3828192 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.25 mg i.v. prochlorperazine
Number of subjects: 8
Study 3828192 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg oral prochlorperazine
Number of subjects: 8
Study 3828192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 11333010 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan (angiotensin II receptor antagonist)
Number of subjects: 272
Study 11333010 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (ACE inhibitor)
Number of subjects: 272
Study 30648598 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat noodles (100 g, replacing one or two meals/day for 10 weeks)
Number of subjects: 84
Study 30648598 — intervention group
Group type: COMPARATOR
Intervention: Wheat noodles (placebo)
Number of subjects: 84
Study 30145267 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard rehabilitative care (physical and occupational therapy and psychoeducation)
Number of subjects: 0
Study 30145267 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary and integrative health therapies (chiropractic, acupuncture, yoga and psychoeducation)
Number of subjects: 0
Study 30145267 — intervention group
Group type: COMPARATOR
Intervention: Alternative treatment (if initial treatment is not effective)
Number of subjects: 0
Study 30145267 — intervention group
Group type: COMPARATOR
Intervention: First-stage treatment plus the alternative treatment (if initial treatment is not effective)
Number of subjects: 0
Study 29383901 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound (US) guided peri-neural axillary plexus block
Number of subjects: 0
Study 29383901 — intervention group
Group type: COMPARATOR
Intervention: Peripheral nerve stimulation (PNS)
Number of subjects: 0
Study 25332249 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab plus chemotherapy (doxorubicin and cyclophosphamide followed by paclitaxel)
Number of subjects: 4046
Study 23038682 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.47 g of intravenous methylprednisolone
Number of subjects: 159
Study 23038682 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.98 g of intravenous methylprednisolone
Number of subjects: 159
Study 23038682 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.25 g of intravenous methylprednisolone
Number of subjects: 159
Study 20368410 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 18
Study 20368410 — intervention group
Group type: COMPARATOR
Intervention: Caloric restriction
Number of subjects: 18
Study 17376268 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymosin-alpha1 1.6 mg by subcutaneous injection twice daily for 1 week
Number of subjects: 42
Study 17376268 — intervention group
Group type: COMPARATOR
Intervention: Control group (broad-spectrum antibiotics only)
Number of subjects: 42
Study 15944096 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealant applied prior to wound closure
Number of subjects: 81
Study 15944096 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fibrin sealant)
Number of subjects: 81
Study 11905433 — intervention group
Group type: EXPERIMENTAL
Intervention: Zaleplon 10 mg
Number of subjects: 30
Study 11905433 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone 7.5 mg
Number of subjects: 30
Study 11905433 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (social dose)
Number of subjects: 30
Study 11905433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 10027482 — intervention group
Group type: EXPERIMENTAL
Intervention: A.S. mouth wash (0.5% silver nitrate)
Number of subjects: 137
Study 10027482 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 137
Study 7491366 — intervention group
Group type: EXPERIMENTAL
Intervention: Actovegin
Number of subjects: 60
Study 7491366 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 2149688 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (400 micrograms per day via continuous subcutaneous infusion)
Number of subjects: 14
Study 2149688 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 14
Study 6992856 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical oxytetracycline oily suspension, twice daily for 7 days each month for 12 months
Number of subjects: 0
Study 6992856 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral doxycycline 5 mg per kilogram of body weight, once a month for 12 months
Number of subjects: 0
Study 6992856 — intervention group
Group type: COMPARATOR
Intervention: Control group received vitamin pills once a month
Number of subjects: 0
Study 31766999 — intervention group
Group type: EXPERIMENTAL
Intervention: Audit and feedback-based intervention including centre-level feedback reports, webinars for facilitated conversations/coaching, and an online repository of curated transition resources.
Number of subjects: 0
Study 31766999 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly detailed in the abstract).
Number of subjects: 0
Study 28553847 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe (EZE) 10 mg/day co-administered with atorvastatin 20 mg for 16 weeks
Number of subjects: 323
Study 28553847 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin monotherapy (20 mg for 16 weeks)
Number of subjects: 323
Study 26019992 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonics training (8 weeks) followed by sight word training (8 weeks)
Number of subjects: 41
Study 26019992 — intervention group
Group type: EXPERIMENTAL
Intervention: Sight word training (8 weeks) followed by phonics training (8 weeks)
Number of subjects: 41
Study 26019992 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined sight word and phonics training
Number of subjects: 41
Study 24209977 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir (400 mg) plus ledipasvir (90 mg) for 8 weeks (group 1)
Number of subjects: 100
Study 24209977 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir (400 mg) plus ledipasvir (90 mg) and ribavirin for 8 weeks (group 2)
Number of subjects: 100
Study 24209977 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir (400 mg) plus ledipasvir (90 mg) for 12 weeks (group 3)
Number of subjects: 100
Study 24209977 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir (400 mg) plus ledipasvir (90 mg) for 12 weeks (group 4)
Number of subjects: 100
Study 24209977 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir (400 mg) plus ledipasvir (90 mg) and ribavirin for 12 weeks (group 5)
Number of subjects: 100
Study 22940818 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) at doses of 6,000 or 12,000 IU administered intravenously within 6 hours after successful percutaneous coronary intervention (PCI)
Number of subjects: 600
Study 22940818 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered intravenously within 6 hours after successful percutaneous coronary intervention (PCI)
Number of subjects: 600
Study 19237568 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59‐H5N1 vaccine
Number of subjects: 0
Study 19237568 — intervention group
Group type: COMPARATOR
Intervention: Plain H5N1 vaccine
Number of subjects: 0
Study 17890472 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled human insulin
Number of subjects: 226
Study 17890472 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous insulin
Number of subjects: 226
Study 15890830 — intervention group
Group type: EXPERIMENTAL
Intervention: Unrestricted oral carbohydrate intake during labor
Number of subjects: 328
Study 15890830 — intervention group
Group type: COMPARATOR
Intervention: Usual care (restricted to ice chips and water)
Number of subjects: 328
Study 11300574 — intervention group
Group type: EXPERIMENTAL
Intervention: Independence-primed participants
Number of subjects: 4
Study 11300574 — intervention group
Group type: COMPARATOR
Intervention: Interdependence-primed participants
Number of subjects: 4
Study 9924225 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 20 micrograms kg‐1
Number of subjects: 100
Study 9924225 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 40 micrograms kg‐1
Number of subjects: 100
Study 9924225 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 100 micrograms kg‐1
Number of subjects: 100
Study 9924225 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 7524159 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (Taxol) 3-hour infusion without G-CSF
Number of subjects: 35
Study 7524159 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (Taxol) 3-hour infusion with G-CSF
Number of subjects: 35
Study 7524159 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (Taxol) 3-hour infusion
Number of subjects: 35
Study 2895993 — intervention group
Group type: EXPERIMENTAL
Intervention: Clorazepate dipotassium (15 to 60 mg/d)
Number of subjects: 0
Study 2895993 — intervention group
Group type: COMPARATOR
Intervention: Buspirone hydrochloride (10 to 40 mg/d)
Number of subjects: 0
Study 31628668 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin 150 mg
Number of subjects: 8
Study 31628668 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin 300 mg
Number of subjects: 8
Study 31628668 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin 600 mg
Number of subjects: 8
Study 31628668 — intervention group
Group type: EXPERIMENTAL
Intervention: Probe drug cocktail (atorvastatin, pitavastatin, rosuvastatin, valsartan)
Number of subjects: 8
Study 31628668 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonlinear regression analysis
Number of subjects: 8
Study 31078149 — intervention group
Group type: EXPERIMENTAL
Intervention: Humic acid (100 mg.L‐1) with CuO nanoparticles (various concentrations)
Number of subjects: 0
Study 31078149 — intervention group
Group type: COMPARATOR
Intervention: CuO nanoparticles (various concentrations) alone
Number of subjects: 0
Study 31078149 — intervention group
Group type: EXPERIMENTAL
Intervention: Humic acid (100 mg.L‐1)
Number of subjects: 0
Study 28327379 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer tablet
Number of subjects: 0
Study 28327379 — intervention group
Group type: COMPARATOR
Intervention: Telephone
Number of subjects: 0
Study 28327379 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 0
Study 25288262 — intervention group
Group type: EXPERIMENTAL
Intervention: 2,790-nm resurfacing laser (double pass treatment at fluences less than or equal to 2.5 mJ with 10% overlap)
Number of subjects: 12
Study 25288262 — intervention group
Group type: EXPERIMENTAL
Intervention: 2,790-nm resurfacing laser (one pass treatment at fluences greater than or equal to 3.0 mJ with 10% overlap)
Number of subjects: 12
Study 23982575 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor physical therapy (PFPT) 2 weeks preoperatively and 2, 4, 6, 8, and 12 weeks postoperatively
Number of subjects: 49
Study 23982575 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care with physician assessment only)
Number of subjects: 49
Study 23982575 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor physical therapy (PFPT)
Number of subjects: 49
Study 21762357 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 40 mg/Amlodipine 5 mg (T40/A5)
Number of subjects: 1097
Study 21762357 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg/Amlodipine 5 mg (T80/A5)
Number of subjects: 1097
Study 21762357 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 5 mg (A5)
Number of subjects: 1097
Study 21762357 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 10 mg (A10)
Number of subjects: 1097
Study 19092234 — intervention group
Group type: EXPERIMENTAL
Intervention: NPPV plus usual dosage of oxygen
Number of subjects: 11
Study 19092234 — intervention group
Group type: COMPARATOR
Intervention: NPPV
Number of subjects: 11
Study 19092234 — intervention group
Group type: COMPARATOR
Intervention: Usual dosage of oxygen
Number of subjects: 11
Study 16934402 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 123
Study 16934402 — intervention group
Group type: COMPARATOR
Intervention: TENS-placebo
Number of subjects: 123
Study 14574511 — intervention group
Group type: EXPERIMENTAL
Intervention: Scintigraphic evaluation using 5, 10, 15, and 20 ml of water containing 0.5 mCi technetium‐99m labelled sulphur colloid
Number of subjects: 34
Study 14574511 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyography (EMG) and laryngeal sensor monitoring (LS)
Number of subjects: 34
Study 14574511 — intervention group
Group type: EXPERIMENTAL
Intervention: Scintigraphic evaluation
Number of subjects: 34
Study 14574511 — intervention group
Group type: EXPERIMENTAL
Intervention: Static thoracic images
Number of subjects: 34
Study 14574511 — intervention group
Group type: COMPARATOR
Intervention: Normal adults (control group)
Number of subjects: 34
Study 10818025 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 3685
Study 8784560 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR test for detection of meningococcal DNA in blood samples
Number of subjects: 80
Study 8784560 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR test for detection of meningococcal DNA in serum samples
Number of subjects: 80
Study 8784560 — intervention group
Group type: COMPARATOR
Intervention: Prior antibiotic treatment
Number of subjects: 80
Study 8784560 — intervention group
Group type: COMPARATOR
Intervention: Conventional techniques for diagnosing meningococcal disease
Number of subjects: 80
Study 8784560 — intervention group
Group type: EXPERIMENTAL
Intervention: Widespread application of the PCR test
Number of subjects: 80
Study 1472394 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group received immediate feedback on cholesterol concentration.
Number of subjects: 578
Study 1472394 — intervention group
Group type: COMPARATOR
Intervention: Control group did not receive feedback on cholesterol concentration.
Number of subjects: 578
Study 1472394 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group with initial cholesterol level of 6.50 mmol l‐1 or greater.
Number of subjects: 578
Study 1472394 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group with initial cholesterol level of less than 5.20 mmol l‐1.
Number of subjects: 578
Study 1472394 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportion of smokers not smoking at follow up in intervention group.
Number of subjects: 578
Study 1472394 — intervention group
Group type: COMPARATOR
Intervention: Proportion of smokers not smoking at follow up in control group.
Number of subjects: 578
Study 6143195 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospice care
Number of subjects: 247
Study 6143195 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 247
Study 31505907 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day concomitant therapy (CT)
Number of subjects: 1141
Study 28741030 — intervention group
Group type: EXPERIMENTAL
Intervention: MIS‐TLIF
Number of subjects: 41
Study 28741030 — intervention group
Group type: COMPARATOR
Intervention: open TLIF
Number of subjects: 41
Study 26437712 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-TT
Number of subjects: 500
Study 26437712 — intervention group
Group type: COMPARATOR
Intervention: MenACWY-PS
Number of subjects: 500
Study 26437712 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 500
Study 24279296 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest X-ray imaging offered to higher-risk patients with chest symptoms
Number of subjects: 0
Study 24279296 — intervention group
Group type: COMPARATOR
Intervention: NICE guidelines for urgent referral for chest X-ray
Number of subjects: 0
Study 21288514 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting covered metal stents (PECMSs)
Number of subjects: 49
Study 21288514 — intervention group
Group type: COMPARATOR
Intervention: Covered metal stents (CCMSs)
Number of subjects: 49
Study 19701237 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg clarithromycin tablets twice a day for 4 days
Number of subjects: 24
Study 19701237 — intervention group
Group type: COMPARATOR
Intervention: Placebo twice daily for 4 days
Number of subjects: 24
Study 17590156 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub-antimicrobial dose doxycycline (SDD)
Number of subjects: 36
Study 17590156 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 14981005 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting of both branches (group A)
Number of subjects: 85
Study 14981005 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting of the main branch with provisional stenting of the side branch (group B)
Number of subjects: 85
Study 14981005 — intervention group
Group type: COMPARATOR
Intervention: Overall
Number of subjects: 85
Study 11800243 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support group (conventional care plus telephone-based support initiated within 48 hours after hospital discharge)
Number of subjects: 256
Study 11800243 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support group
Number of subjects: 256
Study 11800243 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional care)
Number of subjects: 256
Study 11800243 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 256
Study 11800243 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support intervention
Number of subjects: 256
Study 10412726 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipopheresis using the Kaneka Liposorber system
Number of subjects: 20
Study 10412726 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipopheresis
Number of subjects: 20
Study 8575574 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 100 micrograms b.i.d. (n = 55)
Number of subjects: 119
Study 8575574 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 64)
Number of subjects: 119
Study 1663856 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy
Number of subjects: 0
Study 7032811 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-salt diet
Number of subjects: 3
Study 7032811 — intervention group
Group type: COMPARATOR
Intervention: Free sodium diet
Number of subjects: 3
Study 7032811 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute salt loading
Number of subjects: 3
Study 6704545 — intervention group
Group type: COMPARATOR
Intervention: Maintenance therapy with weekly cytosine arabinoside and 6‐thioguanine alone (69 patients)
Number of subjects: 283
Study 6704545 — intervention group
Group type: EXPERIMENTAL
Intervention: Two courses of reduced doses of DAT 1 month apart followed by the same maintenance program (77 patients)
Number of subjects: 283
Study 26752653 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose clazosentan (15 mg/h)
Number of subjects: 2159
Study 27558580 — intervention group
Group type: EXPERIMENTAL
Intervention: 100-kcal portions
Number of subjects: 24
Study 27558580 — intervention group
Group type: EXPERIMENTAL
Intervention: 600-kcal portions
Number of subjects: 24
Study 27558580 — intervention group
Group type: EXPERIMENTAL
Intervention: Scenario 1 (Study 2)
Number of subjects: 24
Study 27558580 — intervention group
Group type: EXPERIMENTAL
Intervention: Scenario 2 (Study 2)
Number of subjects: 24
Study 27558580 — intervention group
Group type: EXPERIMENTAL
Intervention: Scenario 3 (Study 2)
Number of subjects: 24
Study 24794369 — intervention group
Group type: EXPERIMENTAL
Intervention: Tdap vaccination during pregnancy
Number of subjects: 48
Study 24794369 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 22835570 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) applied twice on the cervical erosion with a 1-week interval
Number of subjects: 120
Study 22835570 — intervention group
Group type: COMPARATOR
Intervention: Nd-YAG laser used once for tissue vaporization
Number of subjects: 120
Study 22835570 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 120
Study 22835570 — intervention group
Group type: COMPARATOR
Intervention: Nd-YAG laser
Number of subjects: 120
Study 20420610 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-resistance, high-compliant oxygenator (Quadrox BE-HMO 2000)
Number of subjects: 40
Study 20420610 — intervention group
Group type: COMPARATOR
Intervention: High-resistance, low-compliant oxygenator (Capiox SX18)
Number of subjects: 40
Study 18686348 — intervention group
Group type: EXPERIMENTAL
Intervention: Kiwi Omnicup (KO)
Number of subjects: 164
Study 18686348 — intervention group
Group type: COMPARATOR
Intervention: Malmstrom metal cup (MM)
Number of subjects: 164
Study 15878730 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyeblink conditioning in patients with schizophrenia
Number of subjects: 13
Study 15878730 — intervention group
Group type: COMPARATOR
Intervention: Eyeblink conditioning in controls
Number of subjects: 13
Study 15878730 — intervention group
Group type: EXPERIMENTAL
Intervention: Timing of responses in patients with schizophrenia
Number of subjects: 13
Study 15878730 — intervention group
Group type: COMPARATOR
Intervention: Timing of responses in controls
Number of subjects: 13
Study 12671149 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin plus IVH
Number of subjects: 328
Study 12671149 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin no IVH
Number of subjects: 328
Study 12671149 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline plus IVH
Number of subjects: 328
Study 12671149 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline with no IVH
Number of subjects: 328
Study 10641420 — intervention group
Group type: EXPERIMENTAL
Intervention: Apranax
Number of subjects: 0
Study 10641420 — intervention group
Group type: COMPARATOR
Intervention: Cataflam
Number of subjects: 0
Study 8911108 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating chemotherapy (VIMP) - vincristine, carboplatin, ifosfamide, mesna
Number of subjects: 143